Pharmafile Logo

News and Press Releases

Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV

Results presented today at ESGCT 2025 10 October 2025 -- Paris, France and Lund, Sweden -- Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 10, 2025

Genethon
1 bis, rue de l’Internationale 91000 EVRY-COURCOURONNES

University of Oxford and ReciBioPharm expand strategic collaboration in fight against malaria

Expands the collaboration to manufacture two malaria vaccine candidates (R78C and RH5.1) for Phase 1/2 clinical trials Delivers the sixth malaria vaccine candidate for the University of Oxford Provides drug...

Category: Biotechnology, Clinical Trials, Logistics, Manufacturing and Packing, Pharmaceutical
Posted: June 9, 2025

Recipharm

First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark

21 January 2025 – Copenhagen, Denmark – CSL Behring Denmark today announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec). HEMGENIX®...

Category:
Posted: January 21, 2025

CSL
CSL Global Headquarters, 655 Elizabeth Street, Melbourne VIC 3000 Australia

Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting

HIBISCUS phase 2 data evaluating the safety profile and efficacy of etavopivat in adult and adolescent patients with sickle cell disease FRONTIER4 interim phase 3 results evaluating safety profile and...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 3, 2024

Novo Nordisk
abmo@novonordisk.com
Novo Nordisk A/S Novo Allé, 2880 Bagsvaerd Denmark

ReciBioPharm and GeneVentiv Therapeutics partner to advance first AAV-based gene therapy for haemophilia patients with inhibitors

13 March 2024 -- Stockholm, Sweden -- ReciBioPharm, the advanced and emerging therapies business unit of Recipharm, has announced a collaboration agreement with GeneVentiv Therapeutics, a pre-clinical gene therapy company,...

Category: Biotechnology
Posted: March 13, 2024

Recipharm